SNOA — Sonoma Pharmaceuticals, Inc.

Is SNOA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Oversold As of November 17, 2026

Sonoma Pharmaceuticals, Inc. (SNOA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $0.88. The rating moved from Overbought to Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Sonoma Pharmaceuticals, Inc. (SNOA) is a small-cap specialty pharmaceutical name with limited public financial disclosure and thin liquidity. The combination of potential near-term financing requirements, competitive pressure in dermatology/specialty product channels, and a lack of visible, high-conviction catalysts creates a fragile risk/reward profile. Market-wide sector flows that favor large-cap, M&A-active pharma further reduce the likelihood of sustained institutional interest. Upside would likely require a clear financing plan, a licensing/partnering announcement, or a positive regulatory/clinical readout; absent those, downside from dilution or headline-driven volatility is the principal near-term scenario.

Key factors

  • Limited public financial disclosure and lack of recent EDGAR analysis increases uncertainty around underlying revenue and cash runway.
  • Small-cap / microcap status with low liquidity increases volatility and makes the stock sensitive to dilution or single-event news.
  • Sector themes favor large-cap pharma and defensive healthcare flows, which can divert institutional capital away from small specialty issuers.
  • Potential upside tied to licensing, product approvals or partnership deals; absent visible catalysts, upside visibility is limited.
  • Given the market environment (earnings-driven, modest risk-on), smaller speculative names can underperform if investor focus stays on larger, M&A-active names.

Risks

  • Near-term financing needs leading to dilutive equity raises or onerous convertible financings.
  • Regulatory or clinical setbacks for any product candidates or marketed products.
  • Competitive pressure in dermatology and specialty pharmaceutical channels from better capitalized incumbents.
  • Very low trading liquidity causing wide intra-day moves and difficulty executing larger orders.
  • Weak or opaque financials that could hide cash-burn issues or liabilities.
  • Limited analyst coverage and social sentiment data, increasing reliance on headline-driven price moves.

See today's live rating, score and targets

Members see the live hourly rating for SNOA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.